The Weekly Roundup: July 7-11

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Cold Therapy May Relieve Inflammation in AD

Explore the potential of whole-body cryotherapy as a novel, non-pharmacologic treatment for managing atopic dermatitis symptoms effectively.

APG777 Demonstrates High EASI-75 Response Rates in Moderate to Severe Atopic Dermatitis

New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.

Laser Therapy Gains Ground in Acne Management

Discover the latest advancements in laser treatments for acne vulgaris, focusing on diverse skin types and effective solutions for acne skin of color.

VYNE Unblinds Early VYN202 Data After Safety Pause

VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.

Dermatology Times' Weekly Crossword: July 7, 2025

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Beyond the Label: Evaluating Bimekizumab’s Mental Health Profile in Psoriasis Treatment

Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.

Jasper Investigates Drug Lot Issue in CSU Study

Jasper Therapeutics reveals promising results from briquilimab trials for chronic spontaneous urticaria, showcasing strong efficacy and safety despite manufacturing challenges.

New AI Model Aids Early CSCC Risk Stratification

AI enhances early detection of high-risk cutaneous squamous cell carcinoma (CSCC) by integrating advanced histopathological assessments for improved patient outcomes.

ILDS, ISD Commemorate World Skin Health Day 2025 With ‘No Health without Skin Health’ Theme

World Skin Health Day 2025 unites global leaders to advocate for skin health equity, emphasizing the urgent need for accessible dermatological care worldwide.

Data Shows Spesolimab Maintains Skin Clarity Between GPP Flares

Spesolimab effectively targets IL-36 receptor, reducing inflammation and preventing flares in generalized pustular psoriasis, offering new hope for patients.

Q&A With the NEA: Vetting Eczema-Safe Products Through the Seal of Acceptance

The NEA’s Sam Iannotti, MPH, discusses how the Seal of Acceptance helps patients and clinicians identify products that meet rigorous eczema care standards.

Journal Digest: July 9, 2025

This review of the latest dermatologic studies includes insights into immunomodulatory effects of photodynamic therapy for skin cancer, in vivo and ex vivo sonographic evaluation of tumor margins, and more.

Navigating Changes in Dermatology and Clinical Research Efforts

Explore the latest advancements in dermatology in our July issue, from innovative treatments to AI in skin care, shaping the future of skin health and research.

Optimal Targets Linked to Better AD Outcomes

Achieving optimal treatment targets and minimal disease activity significantly enhances health-related quality of life and satisfaction in patients with atopic dermatitis.

Tralokinumab Shows Hand Relief in ADHAND Trial

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Q&A: Bridging the Gap in Dermatologic Care with a Provider-First Digital Solution

Miiskin is transforming dermatologic care through telehealth, enhancing access, efficiency, and patient relationships, according to Ryan Trowbridge, MD, MS, MA, FAAD.

POLL: Do You Routinely Use Patch Testing When Evaluating Chronic Hand Eczema?

Click here to answer our poll.

Delgocitinib Cream Shows Minimal Systemic Absorption in CHE

Delgocitinib cream offers a safe, effective treatment for chronic hand eczema with minimal systemic absorption, ensuring no significant immunosuppressive effects.

Severe Alopecia Areata Linked to Higher Atopic Dermatitis Risk

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

FDA Opens Access to Over 200 CRLs

FDA enhances transparency by publishing over 200 Complete Response Letters, offering insights into drug approval processes and common deficiencies.

Systemic Therapy for Pediatric Atopic Dermatitis: A Growing Case for Early Intervention

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

Zelsuvmi, First At-Home Prescription Gel for Molluscum Contagiosum, Launches in US

Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.

IL-23 Inhibitor Fails to Improve VASI in Pilot Trial

A pilot study evaluates tildrakizumab's safety and potential in treating stable non-segmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

FDA News and Decisions: Midyear Updates

Exclusive Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first half of 2025.

How GEP Testing is Personalizing Skin Cancer Care Beyond Staging

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

Scalp Disorders in SoC: A Diagnostic Blind Spot

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

Upadacitinib Plus Excimer Laser Efficacious in Treating Refractory Vitiligo With Moderate to Severe Atopic Dermatitis

After 4 months of treatment with the dual therapy, patients with refractory vitiligo exhibited an overall 55% remission rate.

Ethanol-Based Hand Sanitizer Shows No Visible Dermal Toxicity; Further Testing Warranted

Ethanol-based hand sanitizer showed no visible skin toxicity in rats, but subclinical dermatitis raised concerns about dermal test guideline adequacy.

Think Like a CEO: Financial Tips for Physicians

OJM Group’s David Mandell, JD, MBA, shares financial planning strategies for physicians facing new tax laws and market volatility.